Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

bayer ΕΛΛΑΣ ΑΒΕΕ (0000000807) Σώρου 18-20, Μαρούσι, 15125 - loratadine - ΕΠΙΓΛΩΣΣΙΟ ΔΙΣΚΙΟ - 10mg/tab - 0079794755 loratadine 10.000000 mg - loratadine

Ελλάδα - Ελληνικά - Ecolab

ecolab deutschland gmbh -

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

novartis europharm limited - secukinumab - arthritis, psoriatic; psoriasis; spondylitis, ankylosing - Ανοσοκατασταλτικά - plaque psoriasiscosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults and children from the age of 6 years old who are candidates for systemic therapy. hidradenitis suppurativa (hs)cosentyx is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic hs therapy. Ψωριασική arthritiscosentyx, μόνο του ή σε συνδυασμό με μεθοτρεξάτη (mtx), ενδείκνυται για τη θεραπεία της ενεργού ψωριασικής αρθρίτιδας σε ενήλικες ασθενείς όταν η ανταπόκριση σε προηγούμενη τροποποιητική της νόσου αντι ρευματικές φάρμακο (dmard) θεραπεία έχει αποδειχθεί ανεπαρκής. axial spondyloarthritis (axspa)Αγκυλοποιητική σπονδυλίτιδα (as, ακτινολογική axial spondyloarthritis)cosentyx ενδείκνυται για τη θεραπεία της ενεργού αγκυλοποιητικής σπονδυλίτιδας σε ενήλικες που δεν ανταποκρίνονται επαρκώς στη συμβατική θεραπεία. non-radiographic axial spondyloarthritis (nr-axspa)cosentyx is indicated for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) evidence in adults who have responded inadequately to non steroidal anti inflammatory drugs (nsaids). juvenile idiopathic arthritis (jia)enthesitis-related arthritis (era)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active enthesitis-related arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy. juvenile psoriatic arthritis (jpsa)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active juvenile psoriatic arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.

Κύπρος - Ελληνικά - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

medochemie ltd (0000003169) 1-10 constantinoupoleos str, lemesos, 3011, 51409 (3505) - tranexamic acid - solution for injection - 250mg/5ml - tranexamic acid (0001197188) 250mg - tranexamic acid

Κύπρος - Ελληνικά - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

medochemie ltd (0000003169) 1-10 constantinoupoleos str, lemesos, 3011, 51409 (3505) - tranexamic acid - solution for injection - 500mg/5ml - tranexamic acid (0001197188) 500mg - tranexamic acid

Κύπρος - Ελληνικά - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

om pharma sa, lisboa, portugal (0000007737) rua da industria 2, quinta grande, amadora, 2610-088 - etamsilate - tablets - 500mg - etamsilate (0002624444) 500mg - etamsylate

Κύπρος - Ελληνικά - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

om pharma sa, lisboa, portugal (0000007737) rua da industria 2, quinta grande, amadora, 2610-088 - etamsilate - solution for injection - 250mg/2ml - etamsilate (0002624444) 125mg - etamsylate

Κύπρος - Ελληνικά - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

c a papaellinas ltd - ΣΙΔΗΡΟΎΧΑ fumarate - ΣΙΡΟΠΙ - 140mg/5ml - 0000141015 - ferrous fumarate - 140 mg - ferrous fumarate

Κύπρος - Ελληνικά - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

procter & gamble health germany gmbh (0000011290) sulzbacher strasse 40, schwalbach am taunus, 65824 - pyridoxine hydrochloride; cyanocobalamin; thiamine hydrochloride - solution for injection - pyridoxine hydrochloride (0000058560) 100mg; cyanocobalamin (0000068199) 1mg; thiamine hydrochloride (0000067038) 100mg - vit b1 in comb with vitamin b6 and/or vitamin b12

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - upadacitinib - Αρθρίτιδα, ρευματοειδή - Ανοσοκατασταλτικά - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.  crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.